Lacosamide is an anticonvulsant admixture accustomed for the accessory analysis of partial-onset seizures and neuropathic affliction ( not FDA approved).
The U.S. Food and Biologic Administration (FDA) accustomed UCB’s New Biologic Appliance for lacosamide as of November 29, 2007, alpha the approval action for the drug. UCB aswell filed for business approval in the European Union (EU); the European Medicines Agency accustomed the business appliance for analysis in May 2007.
The biologic was accustomed in the EU on September 3, 2008. It was accustomed in the US on October 29, 2008.Lacosamide absolution was delayed attributable to an argument about its adjustment into agenda V of the Controlled Substances Act. The FDA issued their final aphorism of adjustment into Agenda V on June 22, 2009.